chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Client was given the injection, PHN read note by the clients mother stating that client has fainted in the past with injections. Client sat in chair by PHN for about 5 min, no issues or concerns. Client stood up and walked to collect a pencil, PHN still watching client. Client stood waiting for friend for about another 5 mins. As client was walking to exit area, he clasped by doorway. PHN witnessed entire event. Client hit head on door and fell onto abdomen. No apparent injuries. HR 72 and BP 110/72. Client was sweaty. PHN's had client lay on the ground for 10 min and provided water. School Nurse came down and mother was contact and PHN spoke with mother. Client recovered quickly and returned to class.
Fever 100.7 to 101.2,  chills and body aches started at around 9:40p 5/24. On 5/25 fever was 98.8 No chills or body aches, then at 8:35p had slight fever 100.3. I was taking Tylenol. Fever broke this morning 3:00a 5/26. I feel fine now. Temperature is 98.5
8/17/21: 49yoF presenting with allergic reaction s/p 2nd dose of Moderna COVID-19 vaccination. Ptn reports receiving having similar symptoms after the first dose so she took Benadryl prior to receiving her second dose today. Ptn received the vaccination at 1400 today when she began to develop symptoms 10 minutes after vaccination administration reporting scratchy, irritated sensation in her throat causing her to feel like she needs to repeatedly clear it, splotchy rash on her chest, and feeling SOA. Clinic called EMS and she was brought to the ED. Ptn reports she feels the same as she did during initial symptom presentation. Ptn has not taken any medication for symptoms prior to presentation. Reports she feels she needs to keep her neck distended to prevent feeling short of air. She also reports her BP usually runs softer with systolics in the 110s.  Denies lightheadedness, presyncope, N/V/D, abdominal pain.   Clinical Impressions as of Aug 18 2000 Allergic reaction to COVID-19 vaccine     MDM Number of Diagnoses or Management Options Allergic reaction to COVID-19 vaccine Diagnosis management comments:  MS4 MD Candidate 2022   Patient is a 49-year-old woman with history of multiple drug allergies who presents to the emergency department with concerns for an reaction to the COVID-19 vaccine.  Patient is hemodynamically stable and afebrile on presentation.  Patient demonstrates mild facial swelling with no other concerning signs on physical exam.  Patient already has taken 50 mg of by mouth Benadryl at home prior to the onset of her symptoms.  I will provide the patient with IM epinephrine and IV Benadryl and IV Decadron for control of her allergic reaction.  On re-evaluation of the patient she notes that her swelling has significantly improved after her by mouth Benadryl and is not requiring any IM or IV medications.  Patient was re-evaluated and continues to be in the morning.  Patient is comfortable with discharge.  Patient was counseled on likely allergic reaction the COVID-19 vaccination.  Patient was discharged in stable condition with strict return precautions.  Pt is well appearing on exam. Arrives after 2nd Moderna vaccine; she had similar allergic response after 1st dose. Asymptomatic on my exam. No respiratory issues, no n/v or s/s significant allergic event. She refused meds. Pt discharged home.
Came for PE - immunizations given with a few minutes eye rolled back - doctor called from next room - head place between legs then laid on floor with feet elevated - lasted approx 5-7 mins - color pale no SOB - had not eaten or drank anything since noon 7-28-14.
Baby developed a morbiliform rash, temperature of 100.4. Presume viral and not related.
PATIENT STATED THAT HER THROAT FELT LIKE IT WAS STARTING TO CLOSE ABOUT 20 MINUTES AFTER RECEIVING A COVID VACCINE. SHE WAS THEN GIVEN 25MG DIPHENHYDRAMINE AT 9:19 A.M.. AFTER THAT,  SHE WAS GIVEN 1 EPINRPHRINE 0.3MG  PEN AT 9:24. A.M. SHE WAST THEN TAKEN BY AMBULANCE TO HOSPITAL FOR TREATMENT. WILL FOLLOW UP WITH PATIENT
On 9/16/98, pt experienced a breath holding spell followed by a 30 to 60 minute convulsion. An ER or MD visit was required. Pt was given diazepam (Valium) but no outpt therapy. Subsequently, pt recovered. The reporting investigator felt that the breath holding spell and convulsion were possibly related to study vax. Upon internal review, these were considered to be other important medical events. No further info is available.
ADMISSION: 12/23/2021: History of Present Illness  Pt with hx of CVA and HTN came went down at home and upon arrival of EMS after approx 10minutes they started CPR/ACLS.  ROSC was achieved after pt treated for Vfib. Upon arrival to the ED he arrested again and ROSC was again achieved.  He went emergently to the cath lab, STEMI protocol.  12/26/2021: Patient deceased, see Dr note.  Pt's wife notified.  Peripheral IV removed, flexiseal and Foley removed.  R femoral central line remains in place.  Patient's wedding band remains on his L ring finger, I was unable to remove it.  No other pt belongings remaining in the room.  House Supervisor notified that pt is ready for transport to Coroner.
This case was reported by a consumer via call center representative and described the occurrence of joint pain in a 78-year-old male patient who received SHINGRIX for prophylaxis. On 18th October 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, several weeks after receiving SHINGRIX, the patient experienced joint pain, myalgia of lower extremities, muscle stiffness, pain in arm, shoulder pain and fatigue. On an unknown date, the outcome of the joint pain, myalgia of lower extremities, muscle stiffness, pain in arm, shoulder pain and fatigue were unknown. It was unknown if the reporter considered the joint pain, myalgia of lower extremities, muscle stiffness, pain in arm, shoulder pain and fatigue to be related to SHINGRIX. Additional details were reported as follows: The patient exercise 3 times per week with no known health problems. At the time of this report, the patient did not receive a 2nd dose of SHINGRIX. The several weeks after the 1st dose of SHINGRIX the patient started to notice some joint and muscle pain in the thighs and pelvic area. As time went on, these symptoms had gotten worse and now the patient had muscle stiffness and pain in the upper arms, shoulders, thighs along with joint pain. The symptoms were bilateral and symmetric and more pronounced when trying to kneel and getting up out of a chair after sitting for a while. The patient was also noticing some fatigue. The patient never had any of these symptoms before taking the SHINGRIX dose. The patient was asking did you (GSK) had reports of any similar side effects.
1 week after moderna vaccination she developed bilateral leg weakness with tingling. Her bladder function remained normal. Her neurological exam shows leg reflexes at 2-3t suggesting transverse myelities
Rash, itching, sweaty, coughing, vomiting, felt airway closing.   Epi-Pen administered
Red; Itchy; Swollen; Arm was hurting a lot; A spontaneous report was received from a consumer concerning a 70-year-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273)  experienced arm was hurting a lot, red, itchy, swollen.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 17 Jan 2021 prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: unknown) intramuscularly for prophylaxis of COVID-19 infection.    On 17-JAN-2021 the patient experienced arm was hurting a lot and on an unknown date the patient experienced red, itchy, swollen.  No treatment information was provided.  Action taken with RNA-1273 in response to the events was unknown.  The outcome of the event arm was hurting a lot was resolved. The outcome of the events red, itchy and swollen was unknown.; Reporter's Comments: This case concerns a 70-year-old female who experienced nonserious expected events of limb discomfort, injection site swelling, injection site erythema, injection site pruritus. The events occurred the same day as the first dose of mRNA-1273. Treatment not reported.  Arm discomfort resolved, but other event outcomes unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
KNOT AND SWELLING AT SITE, LOW GRADE FEVER, HEADACHE, NAUSEA, DIARRHEA
Tingling running up and down the arm that got the shot (left Bicep) hot spot near wrist and back of shoulder, "pins & needles" all up and down my arm. Still have pain, bicep soreness, and skin eruptions at the present time (12/29/2010).
The vial was initially stored in the refrigerator on 11-Jan-2022 and was administered on 27-Apr-2022; 82 patients administered expired moderna vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (82 patients administered expired moderna vaccine) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 11-Jan-2022 and was administered on 27-Apr-2022) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 084J21A, 035C21A and 038B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Nov-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Apr-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Apr-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (82 patients administered expired moderna vaccine). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 11-Jan-2022 and was administered on 27-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (82 patients administered expired moderna vaccine) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 11-Jan-2022 and was administered on 27-Apr-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient was administered with second booster of Moderna on 27-Apr-2022 Patient was administered with First booster of Moderna on 17-Nov-2021 No concomitant medications were reported. The vial did not undergo any temperature excursions. No patient has reported adverse reaction. No treatment medications were reported.
Tachycardia  High blood pressure  Beginning of anaphylaxis - face tingling, lips tingling, throat itchy, difficulty swallowing, face and neck flushing  Headache Nausea  Treatment- benedryl double dose                             Observed for ??!
Member reported that the day after receiving the vaccine he experienced a fever, his arm was red, painful, warm, and swollen.  No treatment was sought and condition resolved on it's own.
No adverse event; Maternal exposure during breast feeding; This spontaneous case was reported by an other health care professional and describes the occurrence of MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding) and NO ADVERSE EVENT (No adverse event) in a 41-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS5051C) for COVID-19 prophylaxis.     No Medical History information was reported.  On 08-Nov-2022, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 08-Nov-2022, the patient experienced MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). On 08-Nov-2022, MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding) had resolved. At the time of the report, NO ADVERSE EVENT (No adverse event) outcome was unknown.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding).    Concomitant and treatment medications were not reported.   Reporter did not allow further contact
Information has been received from a registered nurse regarding an unknown age and gender patient. On 03-MAR-2012 at 11:30am, ZOSTAVAX, lot # 672477/1604AA was exposed to -12C for an estimated total time out of range of 4 hours. On 17-APR-2012 at 7:30am, ZOSTAVAX, lot # 672477/1604AA was exposed to -12C for an estimated total time out of range of 14 hours. On 20-APR-2012, the patient was administered an out of range dose of ZOSTAVAX, lot# 672477/1604AA expiration date: 13-JAN-2013 (dose and route were not reported). No adverse experience had been reported. This is one of 182 reports from the same source. Additional information has been requested.
Received TD at 05:30pm on 02/24/2003. On 02/25/2003 noticed knot the size of a golf ball, warmth, tenderness, sore muscle.
Vaccine exposure during pregnancy; injection site reaction rash and redness; injection site reaction rash and redness; A spontaneous report (United states) was received from pharmacist concerning herself 40 years old, pregnant, female patient  who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced sore arm and vaccination site reaction.  The patient's medical history was not provided. Concomitant medications were not listed.  on 4 Jan 2021 patient received their first of two planned doses mRNA-1273(Lot number: 026L20A) for prophylaxis of COVID-19 infection.  On 02 Nov 2020 the patient received a positive pregnancy test. Her last menstrual period was on 07 Oct 2021 and conception date was unknown. The patient's estimated due date is 14 Jul 2021.  On 01 Feb 2021,the pregnant patient exposed to their second of two planned doses of mRNA-1273 (Lot number:028L20A ) intramuscularly in the left arm for prophylaxis of COVID-19 infection and experienced sore arm and injection site reaction. She was enrolled in the pregnancy registry. No treatment information provided.  Action taken with mRNA-1273 in response to the events was not applicable.  The outcome of events, exposure during pregnancy was considered resolved on 01 Feb 2021, other events sore arm and injection site reaction was recovered/ resolved on 05 Feb 2021.; Sender's Comments: This case concerns a 40-Year-old female who received mRNA-1273 while pregnant (vaccine exposure during pregnancy) and experienced vaccination site rash and redness.  Positive pregnancy test was 02 Nov 2020, last menstrual period was 07 Oct 2021, and estimated due date is 14 Jul 2021.  The other events are consistent with product profile and temporarily associated with use and causal relationship cannot be excluded. Vaccine exposure during pregnancy is not applicable.
THE PATIENT WAS VERY NERVOUS JUST BEFORE GETTING THE SHOT.  I CALMED HIM DOWN, AND ADMINISTERED THE SHOT, AND  ABOUT 3 OR 4 MINUTES LATER HE SLUMPED AND APPEARED TO PASS OUT.  MY PHARMACY MANAGER, ULISES, AND  I PLACED A COLD PACK WARPPED IN PAPER ON HIS FOREHEAD AND UPPER BACK/SHOULDERS. HE WAS CONSCIOUS AFTER ABOUT A MINUTE OR LESS. WE SPOKE WITH HIS MOTHER, WHO THOUGHT THAT HE WAS DEHYDRATED AND VERY NERVOUS. AS A PRECAUTION, WE CALLED AN AMBULANCE AND THE MEDICAL EMR PERSONNEL EVALUTATED HIS VITALS AND DETERMINED THAT HE WAS OKAY. THEY OFFERED TO TAKE HIM TO THE HOSPITAL IF HIS MOM WANTED TO GO.  SHE DECIDED AGAINST THAT.  SHE SAID THAT SHE'D TAKE HIM HOME AND MAKE SURE THAT HE WAS RE-HYDRATED.
She had 104 temperature; Information has been received from a female patient of unknown age via Pfizer concerning herself. Patient's concurrent conditions, medical history and concomitant medications were not provided.  On an unknown date, the patient was vaccinated with hepatitis b vaccine (recombinant) (RECOMBIVAX HB) for prophylaxis (strength, dose, frequency, route of administration, anatomical location, lot number and expiration date were not provided).  On an unknown date, the patient had a 104 degrees temperature (body temperature abnormal). The outcome of the event was unknown.  Causal relationship between hepatitis b vaccine (recombinant) (RECOMBIVAX HB) and body temperature abnormal was not provided.
Severe pain in the right arm that traveled to the neck, tingling and numbness down the arm that spread down that entire right side of the body and to the right foot. Symptoms began to subside by the morning and by the time the patient called the pharmacy, tingling remained only in her foot.
Developed congestion, a sore throat and many canker sores in his mouth, fatigue reported.
No adverse event; A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were -26Jul2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were -26Jul2022) and NO ADVERSE EVENT (No adverse event) in a 23-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004M21A, 014F21A, 030L20A and 025L20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Jul-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were -26Jul2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were -26Jul2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were -26Jul2022).    No concomitant medicine were reported. Lot number 004M21A, expiration date 13Jul2022. Date of administration of vaccine were - 26Jul2022 (40 doses), 04Aug2022 (1 dose), 19Aug2022 (1 dose), 30Sep2022 (1 dose). No treatment medicine were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-704260 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704260:Master Case
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53-year-old male patient received BNT162b2 (BNT162B2 NOS), in Oct2022 as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: The patient had received the treatment of COVID-19 as Paxlovid on 29Jun2023 to 04Jul2023.  The information on the batch/lot number for [BNT162B2 NOS] has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300250814 same patient, different drug, different event;
My uncle received the vaccine on 26 july. He immediately became unwell and by 1 august, he had lost over 15 lbs. He was admitted to ICU when conditions did not improve. He was put on a breathing machine because he was unable to breathe. His covid test was negative and doctors said it was nothing transmittable. He died early next next morning.
NO ADVERSE EVENT REPORTED.  GAVE VACCINE THAT WAS 1 DAY BEYOND THE 10 WEEKS BEYOND USE DATE AFTER THAWING THE PFIZER COVID VACCINE
9 days after receiving my first moderna shot, I woke up on Saturday 3/20/21 with a red patch and rash at the injection site, my body covered in hives- mostly on my buttocks, thighs, elbows, armpits, forearms. 4 of my toes on my right foot are  red & swollen and painful to walk on. The rash appeared when I woke  up at 8am, and by 11am my face was swollen and red. I did not have any breathing issues. My face swelling subsided within a few hours. The next day on Sunday 3/20/21, the rash on my left upper arm at the injection site has disappeared, but the hives and swelling of the toes have worsened.
This spontaneous report as received from a registered nurse concerning a patient of unknown age who was inadvertently administered a dose of 1 ml PNEUMOVAX23, IM on 15-OCT-2012. No other co-suspects were reported. No concomitant medications were reported. No adverse effect was reported. Additional information is not expected.
I had fever at 101.0 for 5days. Cough, muscle aches and pain.
Fever 101, headache, abdominal pain, chills, muscle aches and fatigue
Day after injection of MENACTRA. Patient developed palpitations, was dizzy, weak and pale. Symptoms resolved in 24 hours.
pt recv vax & was hosp w/fluid on lungs;MD comment on reporting form states CHF devel p/inj;
This is a spontaneous report from a contactable consumer reported that an 89-year-old female patient received PREVNAR 13, (lot number and expiration date were not reported), via an unspecified route of administration on 04Mar2019 at single dose for immunisation. Medical history included sinus infection, have been coughing, have infection for several months, have been bleeding mucus and "the doctor thought that I should have a pneumonia". There were no concomitant medications. That first night after the injection (04Mar2019), she had "chills so much her teeth were chattering" but went back to bed and did not think anything of it. Later on, she developed a "big red patch from the injection site area to the elbow, about 6 inches long". Her tongue was double the size. She saw her cardiologist on 08Mar2019 due to pains in her chest. She went to the ER on 10Mar2019. Since the injection, she is so tired all the time so slept one night for 9 hours and another night for 14 hours. She also has headaches, muscle pain in thighs, is lightheaded, and her heart is racing. She was given a shot in the ER and given antibiotics, which she just finished up. Her tongue still feels swollen now but better than it was. She still feels some effects. She planned to discuss further with her cardiologist for a second opinion. The patient also has been sick for a couple of days. On Sunday morning when the patient's arm was itching really bad where the shot was given, it was bright red and itching. They did lab work in the hospital (later clarified by the consumer as ER). Everything and they said cholesterol dropped 50 points. The outcome of tongue was double the size was recovering and other events was unknown. Information on the batch number has been requested.